
Akihiro Ohashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4328587/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. Molecular Cell, 2006, 22, 719-729.	9.7	724
2	Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nature Communications, 2015, 6, 7668.	12.8	137
3	TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget, 2018, 9, 18480-18493.	1.8	90
4	Fanconi Anemia Complementation Group D2 (FANCD2) Functions Independently of BRCA2- and RAD51-associated Homologous Recombination in Response to DNA Damage. Journal of Biological Chemistry, 2005, 280, 14877-14883.	3.4	77
5	Inactivation of Brca2 Promotes Trp53-Associated but Inhibits KrasG12D-Dependent Pancreatic Cancer Development in Mice. Gastroenterology, 2011, 140, 1303-1313.e3.	1.3	65
6	TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations. Molecular Cancer Research, 2019, 17, 2233-2243.	3.4	49
7	Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Science Advances, 2019, 5, eaav3660.	10.3	48
8	Tex14, a Plk1-Regulated Protein, Is Required for Kinetochore-Microtubule Attachment and Regulation of the Spindle Assembly Checkpoint. Molecular Cell, 2012, 45, 680-695.	9.7	41
9	Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Scientific Reports, 2020, 10, 21762.	3.3	39
10	Oogenesin Is a Novel Mouse Protein Expressed in Oocytes and Early Cleavage-Stage Embryos1. Biology of Reproduction, 2003, 69, 1736-1742.	2.7	38
11	Synthetic Studies on Centromere-Associated Protein-E (CENP-E) Inhibitors: 2. Application of Electrostatic Potential Map (EPM) and Structure-Based Modeling to Imidazo[1,2- <i>a</i>)pyridine Derivatives as Anti-Tumor Agents. Journal of Medicinal Chemistry, 2015, 58, 8036-8053.	6.4	34
12	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Research, 2021, 81, 4835-4848.	0.9	31
13	A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. PLoS ONE, 2015, 10, e0144675.	2.5	31
14	Long-read sequencing for non-small-cell lung cancer genomes. Genome Research, 2020, 30, 1243-1257.	5.5	28
15	Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map. Bioorganic and Medicinal Chemistry, 2013, 21, 5488-5502.	3.0	21
16	Nuclear Accumulation of Cyclin B1 in Mouse Two-Cell Embryos Is Controlled by the Activation of Cdc21. Biology of Reproduction, 2001, 65, 1195-1200.	2.7	19
17	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341.	3.3	17
18	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- <i>d</i>]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent. Journal of Medicinal Chemistry, 2020, 63, 1084-1104.	6.4	16

Akihiro Ohashi

#	Article	IF	CITATIONS
19	A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Science Advances, 2021, 7, .	10.3	15
20	2-Aminomethylthieno[3,2- d]pyrimidin-4(3 H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorganic and Medicinal Chemistry, 2017, 25, 3658-3670.	3.0	13
21	Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorganic and Medicinal Chemistry, 2017, 25, 2133-2147.	3.0	13
22	Different cell fates after mitotic slippage: From aneuploidy to polyploidy. Molecular and Cellular Oncology, 2016, 3, e1088503.	0.7	11
23	Report of the use of patientâ€derived xenograft models in the development of anticancer drugs in Japan. Cancer Science, 2020, 111, 3386-3394.	3.9	10
24	Motor activity of centromere-associated protein-E contributes to its localization at the center of the midbody to regulate cytokinetic abscission. Oncotarget, 2016, 7, 79964-79980.	1.8	9
25	Impacts of the STINGâ€IFNAR1â€STAT1â€IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Cancer Science, 2022, 113, 1352-1361.	3.9	7
26	Design and synthesis of fused bicyclic inhibitors targeting the L5 loop site of centromere-associated protein E. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4296-4300.	2.2	4
27	Cyclin A2 is phosphorylated during the G2/M transition in mouse two-cell embryos. Molecular Reproduction and Development, 2003, 66, 343-348.	2.0	2
28	Abstract 1030: CENP-E inhibition generates micronucleus formation activating the cGAS-STING pathway in cancer cells. , 2021, , .		2
29	Abstract A093: Potential combination partners for a novel CDC7-selective Inhibitor, TAK-931. , 2019, , .		1
30	Expression data of HeLa cells treated with CENP-E siRNA or Eg5 siRNA in the presence of BubR1 siRNA. Genomics Data, 2015, 6, 44-45.	1.3	0
31	Su116 DISSECTING TRANSCROPTOMIC HETEROGENEITY IN PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY SINGLE-CELL RNA SEQUENCING. Gastroenterology, 2021, 160, S-623.	1.3	0
32	Abstract 2048: Property analysis of chromosomal instability-adapted cells using multi-omics approaches. , 2021, , .		0
33	Abstract 3407: A novel CENP-E-selective inhibitor exhibits potent anti-tumor efficacy by two distinct mechanisms of action dependent on spindle assembly checkpoint activity , 2013, , .		0
34	Abstract 3719: TAK-243, a small molecule inhibitor of the ubiquitin activating enzyme (UAE), disrupts DNA damage repair and sensitizes tumor cells and xenografts to ionizing radiation. , 2016, , .		0
35	Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931., 2017, , .		0
36	Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. , 2017, , .		0

AKIHIRO OHASHI

#	Article	IF	CITATIONS
37	Abstract 2312: Phospho-proteomics analysis to determine the signaling pathways affected by a novel CDC7-selective inhibitor TAK-931. , 2018, , .		0
38	Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor. , 2019, , .		0
39	Abstract C113: Multiple modalities of single cell analyses to evaluate the tumor microenvironment in clinical specimens. , 2019, , .		Ο
40	Abstract 3531: A novel germline mutation in the non-coding region ofBRCA2, c40+1 G>A, is associated with hereditary breast cancer. , 2020, , .		0
41	Abstract P029: CDC7 inhibitor-induced replication stress generates inflamed aneuploid cells to sensitize immune checkpoint inhibitors. , 2021, , .		0
42	Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor. , 2019, , .		0
43	Abstract 5635: Combined MEK and mitophagy inhibition promotes mtDNA-mediated innate immunity in <i>KRAS</i> -mutant cancer. Cancer Research, 2022, 82, 5635-5635.	0.9	0